Open AccessFimasartan: A new armament to fight hypertension
Author(s) -
Akshyaya Pradhan,
Vikas Gupta,
Rishi Sethi
Publication year - 2019
Publication title -
journal of family medicine and primary care
Language(s) - English
Resource type - Journals
eISSN - 2278-7135
pISSN - 2249-4863
DOI - 10.4103/jfmpc.jfmpc_300_19
Subject(s) - medicine , angiotensin receptor , pharmacotherapy , angiotensin receptor blockers , diabetes mellitus , pharmacology , intensive care medicine , angiotensin ii , receptor , renin–angiotensin system , endocrinology , blood pressure
Hypertension is a major public health problem of modern era. Fimasartan is a new Angiotensin Receptor Blocker approved for treatment of hypertension. It is more potent and longer acting angiotensin receptor blocker with effects lasting over 24 hours. Many clinical studies have affirmed its role in pharmacotherapy of hypertension. Further, it is renoprotective and has proven beneficial in diabetes also. This article briefly discusses the pharmacology and clinical evidence with fimasartan with a short summary of previous angiotensin receptor blockers.